RYTM RHYTHM PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1649904 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY61.0%
TTM net income YoY-0.8%
TTM EPS YoY6.1%
Revenue 3-yr CAGR65.5%
Net income 3-yr CAGR—
Margins
Gross margin88.2%
Operating margin-66.7%
Net margin-69.0%
FCF margin—
EBITDA margin—
Returns
ROE-163.7%
ROA-40.8%
ROIC (approx.)-83.0%
Asset turnover0.59x
Leverage & solvency
Liabilities / assets54.5%
Debt / equity1.17x
Current ratio2.78x
Interest coverage-10.27x
Cash quality & payout
Operating cash flow / net income0.42x
Accruals ratio-23.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $92.13M | $71.25M | $60.11M | $57.25M | $51.30M | $48.50M | $32.70M | $41.83M |
| Cost of revenue | $12.17M | $8.93M | $7.16M | $4.80M | $5.50M | $5.54M | $3.65M | $3.79M |
| Gross profit | $79.96M | $62.32M | $52.95M | $52.45M | $45.80M | $42.96M | $29.06M | $38.04M |
| R&D expense | $52.48M | $43.43M | $41.73M | $42.03M | $46.03M | $42.31M | $36.97M | $41.17M |
| SG&A expense | $66.75M | $67.45M | $63.59M | $57.48M | $52.42M | $45.95M | $39.09M | $38.13M |
| Operating income | -$39.27M | -$48.55M | -$52.36M | -$47.06M | -$52.65M | -$45.30M | -$47.00M | -$41.26M |
| Interest expense | $4.50M | $4.54M | $4.58M | $4.62M | $4.74M | $5.82M | $5.41M | $5.45M |
| Pretax income | -$40.76M | -$48.85M | -$55.09M | -$47.54M | -$52.79M | -$46.30M | -$49.42M | -$43.38M |
| Income tax | $610,000 | $444,000 | $545,000 | -$31,000 | $111,000 | $337,000 | $80,000 | -$90,000 |
| Net income | -$41.37M | -$49.30M | -$55.64M | -$47.51M | -$52.90M | -$46.63M | -$49.50M | -$43.29M |
| EPS (basic) | -0.61 | -0.73 | -0.83 | — | -0.82 | -0.75 | -0.81 | — |
| EPS (diluted) | -0.61 | -0.73 | -0.83 | — | -0.82 | -0.75 | -0.81 | — |
| Weighted avg. shares (diluted) | 69.05M | 68.59M | 67.97M | — | 66.26M | 63.68M | 63.06M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $39.98M | $65.61M | $62.14M | $54.30M | $52.08M | $135.59M | $106.09M | $89.14M |
| Short-term investments | $280.96M | $265.28M | $278.49M | $334.65M | $363.97M | $155.44M | $208.39M | $231.43M |
| Receivables | $39.12M | $40.41M | $34.19M | $26.08M | $33.03M | $26.12M | $17.82M | $18.51M |
| Inventory | $31.19M | $30.52M | $28.65M | $25.75M | $22.11M | $18.87M | $19.32M | $18.74M |
| Current assets | $419.36M | $426.56M | $430.09M | $466.92M | $494.80M | $360.68M | $369.29M | $374.20M |
| PP&E, net | $569,000 | $103,000 | $1.06M | $1.10M | $237,000 | $297,000 | $462,000 | $632,000 |
| Intangibles | $16.68M | $4.89M | $5.11M | $5.32M | $5.53M | $5.75M | $5.96M | $6.17M |
| Total assets | $443.13M | $437.27M | $442.32M | $480.20M | $506.87M | $372.73M | $386.69M | $392.27M |
| Current liabilities | $150.89M | $123.59M | $103.20M | $105.94M | $104.27M | $129.46M | $111.82M | $115.52M |
| Short-term debt | $14.75M | $12.70M | $10.13M | $7.30M | $5.56M | $3.78M | $1.59M | $1.54M |
| Long-term debt | $87.92M | $93.40M | $98.34M | $100.89M | $103.41M | $106.01M | $107.93M | $108.27M |
| Total debt | $102.67M | $106.10M | $108.47M | $108.18M | $108.97M | $109.79M | $109.52M | $109.81M |
| Total liabilities | $241.59M | $219.97M | $204.70M | $210.17M | $211.19M | $239.15M | $223.60M | $227.72M |
| Shareholders' equity | $87.97M | $102.98M | $122.91M | $139.07M | $148.82M | -$11.91M | $18.95M | $21.73M |
| Net debt | $62.69M | $40.49M | $46.33M | $53.88M | $56.89M | -$25.79M | $3.43M | $20.67M |
| Shares outstanding | 69.31M | 68.82M | 68.45M | 67.21M | 66.68M | 63.91M | 63.49M | 62.39M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.06M | -$9.15M | -$44.19M | -$25.39M | -$26.62M | -$23.31M | -$40.35M | -$18.84M |
| Capital expenditure | — | — | — | $953,000 | — | — | — | — |
| Free cash flow | — | — | — | -$26.34M | — | — | — | — |
| Investing cash flow | -$16.11M | $14.01M | $57.05M | $30.35M | -$246.35M | $54.03M | $24.81M | $21.16M |
| Financing cash flow | -$6.25M | -$1.17M | -$5.40M | -$2.95M | $189.30M | -$889,000 | $32.50M | $38.33M |
| Stock-based compensation | $25.02M | $26.06M | $23.10M | $19.27M | $18.81M | $15.88M | $12.86M | $10.56M |
Free plan shows the latest 8 periods; Pro shows all 43 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.